SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (OTCBB:PURE), today announced the completion of an important facility expansion. The key elements of the expansion include (1) significantly increased capacity for production and blending of PURE’s patented silver dihydrogen citrate (SDC) antimicrobial, (2) a new automated packaging operation and (3) establishment of a dedicated GMP suite for future production of SDC as an active pharmaceutical ingredient.
